FILING ANALYSIS · THURSDAY, NOVEMBER 5
RenovoRx, Inc. RNXT — 8-K: Results of Operations and Financial Condition
positive
RenovoRx reports record Q3 revenue exceeding $1 million, with 26 active commercial cancer center customers and a growing commercial funnel, while maintaining 2026 annual revenue guidance of $3.75M to $4.25M.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →